vs
MVB FINANCIAL CORP（MVBF）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
MVB FINANCIAL CORP的季度营收约是REGENXBIO Inc.的1.2倍（$36.7M vs $30.3M），MVB FINANCIAL CORP净利率更高（0.0% vs -221.3%，领先221.3%），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 2.8%）
MVB金融公司是总部位于美国西弗吉尼亚州的金融控股企业，主要提供商业与零售银行服务、财富管理、抵押贷款及存款产品，同时面向金融科技、游戏领域企业提供专项数字银行解决方案，服务覆盖美国中大西洋地区。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
MVBF vs RGNX — 直观对比
营收规模更大
MVBF
是对方的1.2倍
$30.3M
净利率更高
MVBF
高出221.3%
-221.3%
两年增速更快
RGNX
近两年复合增速
2.8%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $36.7M | $30.3M |
| 净利润 | $0 | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | — | -190.0% |
| 净利率 | 0.0% | -221.3% |
| 营收同比 | — | 43.0% |
| 净利润同比 | — | -31.2% |
| 每股收益（稀释后） | $0.39 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MVBFRGNX
| Q1 26 | $36.7M | — | ||
| Q4 25 | $39.1M | $30.3M | ||
| Q3 25 | $61.2M | $29.7M | ||
| Q2 25 | $33.7M | $21.4M | ||
| Q1 25 | $33.7M | $89.0M | ||
| Q4 24 | $46.2M | $21.2M | ||
| Q3 24 | $33.2M | $24.2M | ||
| Q2 24 | $34.7M | $22.3M |
净利润MVBFRGNX
| Q1 26 | $0 | — | ||
| Q4 25 | $4.2M | $-67.1M | ||
| Q3 25 | $17.1M | $-61.9M | ||
| Q2 25 | $2.0M | $-70.9M | ||
| Q1 25 | $3.6M | $6.1M | ||
| Q4 24 | $9.4M | $-51.2M | ||
| Q3 24 | $2.1M | $-59.6M | ||
| Q2 24 | $4.1M | $-53.0M |
毛利率MVBFRGNX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% |
营业利润率MVBFRGNX
| Q1 26 | — | — | ||
| Q4 25 | 13.9% | -190.0% | ||
| Q3 25 | 38.3% | -176.3% | ||
| Q2 25 | 9.4% | -296.3% | ||
| Q1 25 | 14.3% | 13.6% | ||
| Q4 24 | 26.5% | -242.1% | ||
| Q3 24 | 8.4% | -256.6% | ||
| Q2 24 | 15.9% | -251.3% |
净利率MVBFRGNX
| Q1 26 | 0.0% | — | ||
| Q4 25 | 10.8% | -221.3% | ||
| Q3 25 | 28.0% | -208.3% | ||
| Q2 25 | 5.9% | -331.8% | ||
| Q1 25 | 10.6% | 6.8% | ||
| Q4 24 | 20.4% | -241.3% | ||
| Q3 24 | 6.3% | -246.3% | ||
| Q2 24 | 11.8% | -237.7% |
每股收益（稀释后）MVBFRGNX
| Q1 26 | $0.39 | — | ||
| Q4 25 | $0.32 | $-1.30 | ||
| Q3 25 | $1.32 | $-1.20 | ||
| Q2 25 | $0.15 | $-1.38 | ||
| Q1 25 | $0.27 | $0.12 | ||
| Q4 24 | $0.72 | $-0.99 | ||
| Q3 24 | $0.16 | $-1.17 | ||
| Q2 24 | $0.31 | $-1.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $177.6M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $334.9M | $102.7M |
| 总资产 | $3.3B | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资MVBFRGNX
| Q1 26 | $177.6M | — | ||
| Q4 25 | $244.1M | $230.1M | ||
| Q3 25 | $300.0M | $274.2M | ||
| Q2 25 | $399.4M | $323.3M | ||
| Q1 25 | $251.4M | $267.9M | ||
| Q4 24 | $317.9M | $234.7M | ||
| Q3 24 | $610.9M | $255.5M | ||
| Q2 24 | $455.5M | $290.4M |
股东权益MVBFRGNX
| Q1 26 | $334.9M | — | ||
| Q4 25 | $334.0M | $102.7M | ||
| Q3 25 | $327.8M | $161.5M | ||
| Q2 25 | $302.3M | $213.7M | ||
| Q1 25 | $310.1M | $274.2M | ||
| Q4 24 | $305.7M | $259.7M | ||
| Q3 24 | $303.1M | $301.4M | ||
| Q2 24 | $296.6M | $348.3M |
总资产MVBFRGNX
| Q1 26 | $3.3B | — | ||
| Q4 25 | $3.3B | $453.0M | ||
| Q3 25 | $3.2B | $525.2M | ||
| Q2 25 | $3.2B | $581.0M | ||
| Q1 25 | $3.0B | $490.9M | ||
| Q4 24 | $3.1B | $466.0M | ||
| Q3 24 | $3.4B | $519.1M | ||
| Q2 24 | $3.3B | $569.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-52.8M |
| 自由现金流率自由现金流/营收 | — | -174.0% |
| 资本支出强度资本支出/营收 | — | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-126.4M |
8季度趋势，按日历期对齐
经营现金流MVBFRGNX
| Q1 26 | — | — | ||
| Q4 25 | $4.0M | $-52.3M | ||
| Q3 25 | $-2.6M | $-56.0M | ||
| Q2 25 | $7.4M | $-49.3M | ||
| Q1 25 | $14.1M | $33.6M | ||
| Q4 24 | $-285.0K | $-31.6M | ||
| Q3 24 | $8.6M | $-40.5M | ||
| Q2 24 | $26.9M | $-45.5M |
自由现金流MVBFRGNX
| Q1 26 | — | — | ||
| Q4 25 | $2.1M | $-52.8M | ||
| Q3 25 | $-3.5M | $-56.5M | ||
| Q2 25 | $7.2M | $-49.7M | ||
| Q1 25 | $13.9M | $32.6M | ||
| Q4 24 | $-1.9M | $-32.7M | ||
| Q3 24 | $8.3M | $-40.9M | ||
| Q2 24 | $26.6M | $-46.0M |
自由现金流率MVBFRGNX
| Q1 26 | — | — | ||
| Q4 25 | 5.4% | -174.0% | ||
| Q3 25 | -5.8% | -189.9% | ||
| Q2 25 | 21.5% | -232.8% | ||
| Q1 25 | 41.2% | 36.6% | ||
| Q4 24 | -4.1% | -154.2% | ||
| Q3 24 | 25.1% | -168.9% | ||
| Q2 24 | 76.7% | -206.2% |
资本支出强度MVBFRGNX
| Q1 26 | — | — | ||
| Q4 25 | 4.9% | 1.7% | ||
| Q3 25 | 1.6% | 1.7% | ||
| Q2 25 | 0.6% | 1.8% | ||
| Q1 25 | 0.8% | 1.2% | ||
| Q4 24 | 3.5% | 5.1% | ||
| Q3 24 | 0.9% | 1.3% | ||
| Q2 24 | 0.7% | 2.1% |
现金转化率MVBFRGNX
| Q1 26 | — | — | ||
| Q4 25 | 0.95× | — | ||
| Q3 25 | -0.15× | — | ||
| Q2 25 | 3.72× | — | ||
| Q1 25 | 3.95× | 5.53× | ||
| Q4 24 | -0.03× | — | ||
| Q3 24 | 4.15× | — | ||
| Q2 24 | 6.57× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MVBF
| Net Interest Income | $28.5M | 78% |
| Noninterest Income | $8.2M | 22% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
